nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—PPARG—psoriasis	0.466	1	CbGaD
Repaglinide—ALB—Acitretin—psoriasis	0.0523	0.124	CbGbCtD
Repaglinide—CYP2C8—Tazarotene—psoriasis	0.0511	0.121	CbGbCtD
Repaglinide—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0447	0.106	CbGbCtD
Repaglinide—SLCO1B1—Cyclosporine—psoriasis	0.0339	0.08	CbGbCtD
Repaglinide—ALB—Mycophenolate mofetil—psoriasis	0.0245	0.0578	CbGbCtD
Repaglinide—CYP2C8—Cholecalciferol—psoriasis	0.0218	0.0516	CbGbCtD
Repaglinide—ALB—Prednisone—psoriasis	0.0196	0.0462	CbGbCtD
Repaglinide—CYP2C8—Mycophenolate mofetil—psoriasis	0.0189	0.0447	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—psoriasis	0.0179	0.0424	CbGbCtD
Repaglinide—CYP3A4—Calcitriol—psoriasis	0.0172	0.0406	CbGbCtD
Repaglinide—CYP2C8—Hydrocortisone—psoriasis	0.0152	0.0359	CbGbCtD
Repaglinide—CYP2C8—Cyclosporine—psoriasis	0.0143	0.0339	CbGbCtD
Repaglinide—CYP3A4—Methoxsalen—psoriasis	0.0134	0.0316	CbGbCtD
Repaglinide—ALB—Methotrexate—psoriasis	0.00982	0.0232	CbGbCtD
Repaglinide—CYP2C8—Dexamethasone—psoriasis	0.00944	0.0223	CbGbCtD
Repaglinide—CYP3A4—Cholecalciferol—psoriasis	0.00885	0.0209	CbGbCtD
Repaglinide—CYP3A4—Mycophenolate mofetil—psoriasis	0.00767	0.0181	CbGbCtD
Repaglinide—CYP3A4—Triamcinolone—psoriasis	0.00767	0.0181	CbGbCtD
Repaglinide—CYP3A4—Betamethasone—psoriasis	0.00658	0.0156	CbGbCtD
Repaglinide—CYP3A4—Prednisolone—psoriasis	0.00649	0.0153	CbGbCtD
Repaglinide—CYP3A4—Hydrocortisone—psoriasis	0.00616	0.0145	CbGbCtD
Repaglinide—CYP3A4—Prednisone—psoriasis	0.00613	0.0145	CbGbCtD
Repaglinide—CYP3A4—Cyclosporine—psoriasis	0.00581	0.0137	CbGbCtD
Repaglinide—CYP3A4—Dexamethasone—psoriasis	0.00383	0.00905	CbGbCtD
Repaglinide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000176	0.0016	CcSEcCtD
Repaglinide—Rhinitis—Triamcinolone—psoriasis	0.000176	0.0016	CcSEcCtD
Repaglinide—Headache—Acitretin—psoriasis	0.000176	0.0016	CcSEcCtD
Repaglinide—Headache—Fluocinolone Acetonide—psoriasis	0.000175	0.00159	CcSEcCtD
Repaglinide—Acute coronary syndrome—Betamethasone—psoriasis	0.000175	0.00159	CcSEcCtD
Repaglinide—Acute coronary syndrome—Dexamethasone—psoriasis	0.000175	0.00159	CcSEcCtD
Repaglinide—Eye disorder—Hydrocortisone—psoriasis	0.000175	0.00158	CcSEcCtD
Repaglinide—Myocardial infarction—Dexamethasone—psoriasis	0.000174	0.00158	CcSEcCtD
Repaglinide—Myocardial infarction—Betamethasone—psoriasis	0.000174	0.00158	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—psoriasis	0.000174	0.00157	CcSEcCtD
Repaglinide—Back pain—Mycophenolate mofetil—psoriasis	0.000173	0.00157	CcSEcCtD
Repaglinide—Arrhythmia—Prednisolone—psoriasis	0.000171	0.00155	CcSEcCtD
Repaglinide—Pancreatitis—Prednisone—psoriasis	0.00017	0.00154	CcSEcCtD
Repaglinide—Immune system disorder—Hydrocortisone—psoriasis	0.000169	0.00153	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000168	0.00153	CcSEcCtD
Repaglinide—Arrhythmia—Hydrocortisone—psoriasis	0.000167	0.00151	CcSEcCtD
Repaglinide—Nausea—Acitretin—psoriasis	0.000167	0.00151	CcSEcCtD
Repaglinide—Erythema—Prednisolone—psoriasis	0.000167	0.00151	CcSEcCtD
Repaglinide—Nausea—Fluocinolone Acetonide—psoriasis	0.000166	0.00151	CcSEcCtD
Repaglinide—Paraesthesia—Mycophenolic acid—psoriasis	0.000166	0.0015	CcSEcCtD
Repaglinide—Leukopenia—Cyclosporine—psoriasis	0.000164	0.00149	CcSEcCtD
Repaglinide—Erythema—Hydrocortisone—psoriasis	0.000163	0.00148	CcSEcCtD
Repaglinide—Malnutrition—Hydrocortisone—psoriasis	0.000163	0.00148	CcSEcCtD
Repaglinide—Dyspepsia—Mycophenolic acid—psoriasis	0.000163	0.00147	CcSEcCtD
Repaglinide—Hypersensitivity—Hydroxyurea—psoriasis	0.000162	0.00147	CcSEcCtD
Repaglinide—Leukopenia—Mycophenolate mofetil—psoriasis	0.00016	0.00145	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000159	0.00145	CcSEcCtD
Repaglinide—Hypertension—Cyclosporine—psoriasis	0.000158	0.00143	CcSEcCtD
Repaglinide—Constipation—Mycophenolic acid—psoriasis	0.000158	0.00143	CcSEcCtD
Repaglinide—Palpitations—Mycophenolate mofetil—psoriasis	0.000158	0.00143	CcSEcCtD
Repaglinide—Arrhythmia—Triamcinolone—psoriasis	0.000157	0.00143	CcSEcCtD
Repaglinide—Hyperglycaemia—Prednisone—psoriasis	0.000157	0.00142	CcSEcCtD
Repaglinide—Arthralgia—Cyclosporine—psoriasis	0.000156	0.00141	CcSEcCtD
Repaglinide—Chest pain—Cyclosporine—psoriasis	0.000156	0.00141	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000155	0.0014	CcSEcCtD
Repaglinide—Hypertension—Mycophenolate mofetil—psoriasis	0.000154	0.0014	CcSEcCtD
Repaglinide—Visual impairment—Betamethasone—psoriasis	0.000154	0.0014	CcSEcCtD
Repaglinide—Visual impairment—Dexamethasone—psoriasis	0.000154	0.0014	CcSEcCtD
Repaglinide—Erythema—Triamcinolone—psoriasis	0.000153	0.00139	CcSEcCtD
Repaglinide—Acute coronary syndrome—Prednisone—psoriasis	0.000153	0.00139	CcSEcCtD
Repaglinide—Chest pain—Mycophenolate mofetil—psoriasis	0.000152	0.00138	CcSEcCtD
Repaglinide—Arthralgia—Mycophenolate mofetil—psoriasis	0.000152	0.00138	CcSEcCtD
Repaglinide—Myocardial infarction—Prednisone—psoriasis	0.000152	0.00138	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000151	0.00137	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000151	0.00137	CcSEcCtD
Repaglinide—Diarrhoea—Hydroxyurea—psoriasis	0.000151	0.00137	CcSEcCtD
Repaglinide—Oedema—Cyclosporine—psoriasis	0.000149	0.00136	CcSEcCtD
Repaglinide—Anaphylactic shock—Cyclosporine—psoriasis	0.000149	0.00136	CcSEcCtD
Repaglinide—Eye disorder—Dexamethasone—psoriasis	0.000149	0.00135	CcSEcCtD
Repaglinide—Eye disorder—Betamethasone—psoriasis	0.000149	0.00135	CcSEcCtD
Repaglinide—Back pain—Triamcinolone—psoriasis	0.000148	0.00134	CcSEcCtD
Repaglinide—Thrombocytopenia—Cyclosporine—psoriasis	0.000146	0.00133	CcSEcCtD
Repaglinide—Abdominal pain—Mycophenolic acid—psoriasis	0.000146	0.00132	CcSEcCtD
Repaglinide—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000146	0.00132	CcSEcCtD
Repaglinide—Oedema—Mycophenolate mofetil—psoriasis	0.000146	0.00132	CcSEcCtD
Repaglinide—Skin disorder—Cyclosporine—psoriasis	0.000145	0.00132	CcSEcCtD
Repaglinide—Hypertension—Prednisolone—psoriasis	0.000144	0.0013	CcSEcCtD
Repaglinide—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000143	0.00129	CcSEcCtD
Repaglinide—Arrhythmia—Dexamethasone—psoriasis	0.000143	0.00129	CcSEcCtD
Repaglinide—Arrhythmia—Betamethasone—psoriasis	0.000143	0.00129	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—psoriasis	0.000142	0.00129	CcSEcCtD
Repaglinide—Skin disorder—Mycophenolate mofetil—psoriasis	0.000142	0.00128	CcSEcCtD
Repaglinide—Alopecia—Betamethasone—psoriasis	0.000141	0.00128	CcSEcCtD
Repaglinide—Alopecia—Dexamethasone—psoriasis	0.000141	0.00128	CcSEcCtD
Repaglinide—Hypertension—Hydrocortisone—psoriasis	0.00014	0.00127	CcSEcCtD
Repaglinide—Vomiting—Hydroxyurea—psoriasis	0.00014	0.00127	CcSEcCtD
Repaglinide—Rash—Hydroxyurea—psoriasis	0.000139	0.00126	CcSEcCtD
Repaglinide—Erythema—Betamethasone—psoriasis	0.000139	0.00126	CcSEcCtD
Repaglinide—Erythema—Dexamethasone—psoriasis	0.000139	0.00126	CcSEcCtD
Repaglinide—Dermatitis—Hydroxyurea—psoriasis	0.000139	0.00126	CcSEcCtD
Repaglinide—Headache—Hydroxyurea—psoriasis	0.000138	0.00125	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000138	0.00125	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000136	0.00123	CcSEcCtD
Repaglinide—Oedema—Prednisolone—psoriasis	0.000136	0.00123	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisolone—psoriasis	0.000136	0.00123	CcSEcCtD
Repaglinide—Paraesthesia—Cyclosporine—psoriasis	0.000134	0.00122	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000133	0.0012	CcSEcCtD
Repaglinide—Anaphylactic shock—Hydrocortisone—psoriasis	0.000133	0.0012	CcSEcCtD
Repaglinide—Oedema—Hydrocortisone—psoriasis	0.000133	0.0012	CcSEcCtD
Repaglinide—Hypertension—Triamcinolone—psoriasis	0.000132	0.0012	CcSEcCtD
Repaglinide—Dyspepsia—Cyclosporine—psoriasis	0.000131	0.00119	CcSEcCtD
Repaglinide—Nausea—Hydroxyurea—psoriasis	0.000131	0.00119	CcSEcCtD
Repaglinide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000131	0.00119	CcSEcCtD
Repaglinide—Pruritus—Mycophenolic acid—psoriasis	0.000131	0.00119	CcSEcCtD
Repaglinide—Eye disorder—Prednisone—psoriasis	0.00013	0.00118	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000129	0.00117	CcSEcCtD
Repaglinide—Skin disorder—Hydrocortisone—psoriasis	0.000129	0.00117	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000128	0.00116	CcSEcCtD
Repaglinide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000128	0.00116	CcSEcCtD
Repaglinide—Constipation—Cyclosporine—psoriasis	0.000128	0.00116	CcSEcCtD
Repaglinide—Diarrhoea—Mycophenolic acid—psoriasis	0.000126	0.00115	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000126	0.00114	CcSEcCtD
Repaglinide—Immune system disorder—Prednisone—psoriasis	0.000126	0.00114	CcSEcCtD
Repaglinide—Oedema—Triamcinolone—psoriasis	0.000125	0.00113	CcSEcCtD
Repaglinide—Anaphylactic shock—Triamcinolone—psoriasis	0.000125	0.00113	CcSEcCtD
Repaglinide—Constipation—Mycophenolate mofetil—psoriasis	0.000125	0.00113	CcSEcCtD
Repaglinide—Arrhythmia—Prednisone—psoriasis	0.000124	0.00113	CcSEcCtD
Repaglinide—Alopecia—Prednisone—psoriasis	0.000123	0.00111	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—psoriasis	0.000122	0.00111	CcSEcCtD
Repaglinide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000122	0.00111	CcSEcCtD
Repaglinide—Paraesthesia—Prednisolone—psoriasis	0.000122	0.00111	CcSEcCtD
Repaglinide—Erythema—Prednisone—psoriasis	0.000121	0.0011	CcSEcCtD
Repaglinide—Malnutrition—Prednisone—psoriasis	0.000121	0.0011	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000121	0.0011	CcSEcCtD
Repaglinide—Hypertension—Betamethasone—psoriasis	0.00012	0.00109	CcSEcCtD
Repaglinide—Hypertension—Dexamethasone—psoriasis	0.00012	0.00109	CcSEcCtD
Repaglinide—Paraesthesia—Hydrocortisone—psoriasis	0.000119	0.00108	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000119	0.00108	CcSEcCtD
Repaglinide—Urticaria—Cyclosporine—psoriasis	0.000119	0.00108	CcSEcCtD
Repaglinide—Abdominal pain—Cyclosporine—psoriasis	0.000118	0.00107	CcSEcCtD
Repaglinide—Vomiting—Mycophenolic acid—psoriasis	0.000117	0.00107	CcSEcCtD
Repaglinide—Dyspepsia—Hydrocortisone—psoriasis	0.000117	0.00106	CcSEcCtD
Repaglinide—Rash—Mycophenolic acid—psoriasis	0.000116	0.00106	CcSEcCtD
Repaglinide—Dermatitis—Mycophenolic acid—psoriasis	0.000116	0.00106	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—psoriasis	0.000116	0.00105	CcSEcCtD
Repaglinide—Urticaria—Mycophenolate mofetil—psoriasis	0.000116	0.00105	CcSEcCtD
Repaglinide—Headache—Mycophenolic acid—psoriasis	0.000116	0.00105	CcSEcCtD
Repaglinide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000115	0.00105	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000115	0.00104	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000114	0.00103	CcSEcCtD
Repaglinide—Oedema—Dexamethasone—psoriasis	0.000113	0.00103	CcSEcCtD
Repaglinide—Oedema—Betamethasone—psoriasis	0.000113	0.00103	CcSEcCtD
Repaglinide—Anaphylactic shock—Betamethasone—psoriasis	0.000113	0.00103	CcSEcCtD
Repaglinide—Anaphylactic shock—Dexamethasone—psoriasis	0.000113	0.00103	CcSEcCtD
Repaglinide—Paraesthesia—Triamcinolone—psoriasis	0.000112	0.00102	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—psoriasis	0.000112	0.00102	CcSEcCtD
Repaglinide—Thrombocytopenia—Dexamethasone—psoriasis	0.000111	0.00101	CcSEcCtD
Repaglinide—Thrombocytopenia—Betamethasone—psoriasis	0.000111	0.00101	CcSEcCtD
Repaglinide—Hypersensitivity—Cyclosporine—psoriasis	0.00011	0.000998	CcSEcCtD
Repaglinide—Dyspepsia—Triamcinolone—psoriasis	0.00011	0.000998	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—psoriasis	0.00011	0.000997	CcSEcCtD
Repaglinide—Nausea—Mycophenolic acid—psoriasis	0.00011	0.000995	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—psoriasis	0.000109	0.000985	CcSEcCtD
Repaglinide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000109	0.000985	CcSEcCtD
Repaglinide—Urticaria—Prednisolone—psoriasis	0.000108	0.00098	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—psoriasis	0.000108	0.000978	CcSEcCtD
Repaglinide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000107	0.000974	CcSEcCtD
Repaglinide—Pruritus—Cyclosporine—psoriasis	0.000106	0.000959	CcSEcCtD
Repaglinide—Urticaria—Hydrocortisone—psoriasis	0.000105	0.000957	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—psoriasis	0.000105	0.000952	CcSEcCtD
Repaglinide—Abdominal pain—Hydrocortisone—psoriasis	0.000105	0.000952	CcSEcCtD
Repaglinide—Hypertension—Prednisone—psoriasis	0.000104	0.000948	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000103	0.000937	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000103	0.000937	CcSEcCtD
Repaglinide—Pruritus—Mycophenolate mofetil—psoriasis	0.000103	0.000935	CcSEcCtD
Repaglinide—Arthralgia—Prednisone—psoriasis	0.000103	0.000935	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—psoriasis	0.000103	0.000931	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000102	0.000928	CcSEcCtD
Repaglinide—Diarrhoea—Cyclosporine—psoriasis	0.000102	0.000927	CcSEcCtD
Repaglinide—Paraesthesia—Dexamethasone—psoriasis	0.000102	0.000924	CcSEcCtD
Repaglinide—Paraesthesia—Betamethasone—psoriasis	0.000102	0.000924	CcSEcCtD
Repaglinide—Erythema—Methotrexate—psoriasis	0.000101	0.000918	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—psoriasis	0.000101	0.000918	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisolone—psoriasis	0.0001	0.000909	CcSEcCtD
Repaglinide—Dyspepsia—Betamethasone—psoriasis	9.98e-05	0.000906	CcSEcCtD
Repaglinide—Dyspepsia—Dexamethasone—psoriasis	9.98e-05	0.000906	CcSEcCtD
Repaglinide—Diarrhoea—Mycophenolate mofetil—psoriasis	9.97e-05	0.000904	CcSEcCtD
Repaglinide—Urticaria—Triamcinolone—psoriasis	9.93e-05	0.000901	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisone—psoriasis	9.88e-05	0.000896	CcSEcCtD
Repaglinide—Oedema—Prednisone—psoriasis	9.88e-05	0.000896	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Dexamethasone—psoriasis	9.79e-05	0.000888	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Betamethasone—psoriasis	9.79e-05	0.000888	CcSEcCtD
Repaglinide—Back pain—Methotrexate—psoriasis	9.78e-05	0.000888	CcSEcCtD
Repaglinide—Hypersensitivity—Hydrocortisone—psoriasis	9.78e-05	0.000887	CcSEcCtD
Repaglinide—Skin disorder—Prednisone—psoriasis	9.59e-05	0.00087	CcSEcCtD
Repaglinide—Vomiting—Cyclosporine—psoriasis	9.5e-05	0.000862	CcSEcCtD
Repaglinide—Rash—Cyclosporine—psoriasis	9.42e-05	0.000854	CcSEcCtD
Repaglinide—Dermatitis—Cyclosporine—psoriasis	9.41e-05	0.000854	CcSEcCtD
Repaglinide—Pruritus—Hydrocortisone—psoriasis	9.39e-05	0.000852	CcSEcCtD
Repaglinide—Headache—Cyclosporine—psoriasis	9.36e-05	0.000849	CcSEcCtD
Repaglinide—Gastrointestinal pain—Betamethasone—psoriasis	9.27e-05	0.000841	CcSEcCtD
Repaglinide—Gastrointestinal pain—Dexamethasone—psoriasis	9.27e-05	0.000841	CcSEcCtD
Repaglinide—Vomiting—Mycophenolate mofetil—psoriasis	9.26e-05	0.000841	CcSEcCtD
Repaglinide—Hypersensitivity—Triamcinolone—psoriasis	9.21e-05	0.000835	CcSEcCtD
Repaglinide—Rash—Mycophenolate mofetil—psoriasis	9.19e-05	0.000834	CcSEcCtD
Repaglinide—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	9.18e-05	0.0851	CbGpPWpGaD
Repaglinide—Dermatitis—Mycophenolate mofetil—psoriasis	9.18e-05	0.000833	CcSEcCtD
Repaglinide—Headache—Mycophenolate mofetil—psoriasis	9.13e-05	0.000828	CcSEcCtD
Repaglinide—Diarrhoea—Hydrocortisone—psoriasis	9.08e-05	0.000824	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—psoriasis	9.05e-05	0.000821	CcSEcCtD
Repaglinide—Urticaria—Dexamethasone—psoriasis	9.01e-05	0.000817	CcSEcCtD
Repaglinide—Urticaria—Betamethasone—psoriasis	9.01e-05	0.000817	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Prednisone—psoriasis	9e-05	0.000816	CcSEcCtD
Repaglinide—Abdominal pain—Dexamethasone—psoriasis	8.96e-05	0.000813	CcSEcCtD
Repaglinide—Abdominal pain—Betamethasone—psoriasis	8.96e-05	0.000813	CcSEcCtD
Repaglinide—Nausea—Cyclosporine—psoriasis	8.87e-05	0.000805	CcSEcCtD
Repaglinide—Paraesthesia—Prednisone—psoriasis	8.87e-05	0.000805	CcSEcCtD
Repaglinide—Pruritus—Triamcinolone—psoriasis	8.84e-05	0.000802	CcSEcCtD
Repaglinide—Dyspepsia—Prednisone—psoriasis	8.69e-05	0.000789	CcSEcCtD
Repaglinide—Nausea—Mycophenolate mofetil—psoriasis	8.65e-05	0.000785	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—psoriasis	8.61e-05	0.000781	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—psoriasis	8.61e-05	0.000781	CcSEcCtD
Repaglinide—Rash—Prednisolone—psoriasis	8.57e-05	0.000778	CcSEcCtD
Repaglinide—Dermatitis—Prednisolone—psoriasis	8.56e-05	0.000777	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.55e-05	0.000776	CcSEcCtD
Repaglinide—Headache—Prednisolone—psoriasis	8.51e-05	0.000773	CcSEcCtD
Repaglinide—Constipation—Prednisone—psoriasis	8.45e-05	0.000766	CcSEcCtD
Repaglinide—Vomiting—Hydrocortisone—psoriasis	8.44e-05	0.000766	CcSEcCtD
Repaglinide—Rash—Hydrocortisone—psoriasis	8.37e-05	0.000759	CcSEcCtD
Repaglinide—Dermatitis—Hydrocortisone—psoriasis	8.36e-05	0.000759	CcSEcCtD
Repaglinide—Headache—Hydrocortisone—psoriasis	8.32e-05	0.000754	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—psoriasis	8.25e-05	0.000749	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—psoriasis	8.08e-05	0.000733	CcSEcCtD
Repaglinide—Gastrointestinal pain—Prednisone—psoriasis	8.08e-05	0.000733	CcSEcCtD
Repaglinide—Nausea—Prednisolone—psoriasis	8.07e-05	0.000732	CcSEcCtD
Repaglinide—Pruritus—Betamethasone—psoriasis	8.02e-05	0.000728	CcSEcCtD
Repaglinide—Pruritus—Dexamethasone—psoriasis	8.02e-05	0.000728	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—psoriasis	8.02e-05	0.000727	CcSEcCtD
Repaglinide—Vomiting—Triamcinolone—psoriasis	7.95e-05	0.000721	CcSEcCtD
Repaglinide—Nausea—Hydrocortisone—psoriasis	7.88e-05	0.000715	CcSEcCtD
Repaglinide—Rash—Triamcinolone—psoriasis	7.88e-05	0.000715	CcSEcCtD
Repaglinide—Dermatitis—Triamcinolone—psoriasis	7.87e-05	0.000714	CcSEcCtD
Repaglinide—Urticaria—Prednisone—psoriasis	7.85e-05	0.000712	CcSEcCtD
Repaglinide—Headache—Triamcinolone—psoriasis	7.83e-05	0.00071	CcSEcCtD
Repaglinide—Abdominal pain—Prednisone—psoriasis	7.81e-05	0.000708	CcSEcCtD
Repaglinide—Diarrhoea—Dexamethasone—psoriasis	7.76e-05	0.000704	CcSEcCtD
Repaglinide—Diarrhoea—Betamethasone—psoriasis	7.76e-05	0.000704	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—psoriasis	7.52e-05	0.000682	CcSEcCtD
Repaglinide—Nausea—Triamcinolone—psoriasis	7.42e-05	0.000674	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—psoriasis	7.41e-05	0.000672	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisone—psoriasis	7.28e-05	0.00066	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—psoriasis	7.27e-05	0.000659	CcSEcCtD
Repaglinide—Vomiting—Dexamethasone—psoriasis	7.21e-05	0.000654	CcSEcCtD
Repaglinide—Vomiting—Betamethasone—psoriasis	7.21e-05	0.000654	CcSEcCtD
Repaglinide—Rash—Dexamethasone—psoriasis	7.15e-05	0.000649	CcSEcCtD
Repaglinide—Rash—Betamethasone—psoriasis	7.15e-05	0.000649	CcSEcCtD
Repaglinide—Dermatitis—Dexamethasone—psoriasis	7.14e-05	0.000648	CcSEcCtD
Repaglinide—Dermatitis—Betamethasone—psoriasis	7.14e-05	0.000648	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—psoriasis	7.13e-05	0.000647	CcSEcCtD
Repaglinide—Headache—Dexamethasone—psoriasis	7.1e-05	0.000645	CcSEcCtD
Repaglinide—Headache—Betamethasone—psoriasis	7.1e-05	0.000645	CcSEcCtD
Repaglinide—Pruritus—Prednisone—psoriasis	6.99e-05	0.000634	CcSEcCtD
Repaglinide—Diarrhoea—Prednisone—psoriasis	6.76e-05	0.000613	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—psoriasis	6.75e-05	0.000612	CcSEcCtD
Repaglinide—Nausea—Dexamethasone—psoriasis	6.74e-05	0.000611	CcSEcCtD
Repaglinide—Nausea—Betamethasone—psoriasis	6.74e-05	0.000611	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—psoriasis	6.56e-05	0.000595	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—psoriasis	6.52e-05	0.000592	CcSEcCtD
Repaglinide—Vomiting—Prednisone—psoriasis	6.28e-05	0.00057	CcSEcCtD
Repaglinide—Rash—Prednisone—psoriasis	6.23e-05	0.000565	CcSEcCtD
Repaglinide—Dermatitis—Prednisone—psoriasis	6.22e-05	0.000564	CcSEcCtD
Repaglinide—Headache—Prednisone—psoriasis	6.19e-05	0.000561	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—psoriasis	6.08e-05	0.000552	CcSEcCtD
Repaglinide—Nausea—Prednisone—psoriasis	5.87e-05	0.000532	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—psoriasis	5.84e-05	0.00053	CcSEcCtD
Repaglinide—CYP2C8—Xenobiotics—CYP2S1—psoriasis	5.69e-05	0.0527	CbGpPWpGaD
Repaglinide—Diarrhoea—Methotrexate—psoriasis	5.65e-05	0.000512	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—psoriasis	5.25e-05	0.000476	CcSEcCtD
Repaglinide—Rash—Methotrexate—psoriasis	5.2e-05	0.000472	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—psoriasis	5.2e-05	0.000472	CcSEcCtD
Repaglinide—Headache—Methotrexate—psoriasis	5.17e-05	0.000469	CcSEcCtD
Repaglinide—Nausea—Methotrexate—psoriasis	4.9e-05	0.000445	CcSEcCtD
Repaglinide—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	3.29e-05	0.0305	CbGpPWpGaD
Repaglinide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	3.05e-05	0.0283	CbGpPWpGaD
Repaglinide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	2.97e-05	0.0275	CbGpPWpGaD
Repaglinide—PPARG—Transcription factor regulation in adipogenesis—LEP—psoriasis	2.72e-05	0.0252	CbGpPWpGaD
Repaglinide—PPARG—Differentiation of white and brown adipocyte   —LEP—psoriasis	2.46e-05	0.0228	CbGpPWpGaD
Repaglinide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.4e-05	0.0222	CbGpPWpGaD
Repaglinide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	2.36e-05	0.0219	CbGpPWpGaD
Repaglinide—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	2.33e-05	0.0216	CbGpPWpGaD
Repaglinide—PPARG—Nuclear Receptors—VDR—psoriasis	2.19e-05	0.0203	CbGpPWpGaD
Repaglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	2.09e-05	0.0194	CbGpPWpGaD
Repaglinide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	1.92e-05	0.0177	CbGpPWpGaD
Repaglinide—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	1.73e-05	0.0161	CbGpPWpGaD
Repaglinide—KCNJ11—Type II diabetes mellitus—TNF—psoriasis	1.7e-05	0.0158	CbGpPWpGaD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	1.67e-05	0.0154	CbGpPWpGaD
Repaglinide—ALB—HDL-mediated lipid transport—APOE—psoriasis	1.66e-05	0.0154	CbGpPWpGaD
Repaglinide—PPARG—PPARA activates gene expression—CARM1—psoriasis	1.57e-05	0.0146	CbGpPWpGaD
Repaglinide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	1.54e-05	0.0142	CbGpPWpGaD
Repaglinide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	1.27e-05	0.0118	CbGpPWpGaD
Repaglinide—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	1.26e-05	0.0117	CbGpPWpGaD
Repaglinide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	1.25e-05	0.0116	CbGpPWpGaD
Repaglinide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	1.1e-05	0.0102	CbGpPWpGaD
Repaglinide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	1.06e-05	0.00981	CbGpPWpGaD
Repaglinide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	1.03e-05	0.00953	CbGpPWpGaD
Repaglinide—CYP2C8—Biological oxidations—CYP2S1—psoriasis	1.02e-05	0.00943	CbGpPWpGaD
Repaglinide—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	1.02e-05	0.00941	CbGpPWpGaD
Repaglinide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	1.01e-05	0.0094	CbGpPWpGaD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	1.01e-05	0.00934	CbGpPWpGaD
Repaglinide—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	1e-05	0.0093	CbGpPWpGaD
Repaglinide—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	1e-05	0.0093	CbGpPWpGaD
Repaglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	9.98e-06	0.00925	CbGpPWpGaD
Repaglinide—ALB—Lipoprotein metabolism—APOE—psoriasis	9.55e-06	0.00885	CbGpPWpGaD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	9.37e-06	0.00868	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—SOCS1—psoriasis	8.9e-06	0.00824	CbGpPWpGaD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	8.71e-06	0.00807	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SERPINB8—psoriasis	7.79e-06	0.00722	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—TARS—psoriasis	7.68e-06	0.00711	CbGpPWpGaD
Repaglinide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	7.44e-06	0.00689	CbGpPWpGaD
Repaglinide—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	6.98e-06	0.00646	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—LEP—psoriasis	6.57e-06	0.00608	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—CAT—psoriasis	6.54e-06	0.00606	CbGpPWpGaD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	6.52e-06	0.00604	CbGpPWpGaD
Repaglinide—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	6.51e-06	0.00604	CbGpPWpGaD
Repaglinide—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	6.41e-06	0.00594	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—CRP—psoriasis	6.38e-06	0.00591	CbGpPWpGaD
Repaglinide—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	6.35e-06	0.00588	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—NDUFA5—psoriasis	6.31e-06	0.00585	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—APOE—psoriasis	6.25e-06	0.00579	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NDUFA5—psoriasis	6.12e-06	0.00567	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—IL4—psoriasis	6.01e-06	0.00557	CbGpPWpGaD
Repaglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	5.94e-06	0.0055	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	5.87e-06	0.00544	CbGpPWpGaD
Repaglinide—ABCC8—Transmembrane transport of small molecules—CP—psoriasis	5.87e-06	0.00543	CbGpPWpGaD
Repaglinide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.83e-06	0.0054	CbGpPWpGaD
Repaglinide—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	5.76e-06	0.00534	CbGpPWpGaD
Repaglinide—ABCC8—Transmembrane transport of small molecules—CARM1—psoriasis	5.6e-06	0.00518	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.46e-06	0.00506	CbGpPWpGaD
Repaglinide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.39e-06	0.00499	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CYP2S1—psoriasis	5.37e-06	0.00497	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CYP2S1—psoriasis	5.2e-06	0.00482	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—CAT—psoriasis	5.2e-06	0.00481	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—CRP—psoriasis	5.19e-06	0.00481	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—CARM1—psoriasis	5.02e-06	0.00465	CbGpPWpGaD
Repaglinide—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	4.98e-06	0.00462	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—ICAM1—psoriasis	4.77e-06	0.00442	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—CARM1—psoriasis	4.72e-06	0.00438	CbGpPWpGaD
Repaglinide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.71e-06	0.00437	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—LEP—psoriasis	4.63e-06	0.00429	CbGpPWpGaD
Repaglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	4.62e-06	0.00428	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NDUFA5—psoriasis	4.52e-06	0.00419	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.46e-06	0.00414	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—NOS2—psoriasis	4.32e-06	0.004	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.22e-06	0.00391	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—CRP—psoriasis	4.13e-06	0.00382	CbGpPWpGaD
Repaglinide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.06e-06	0.00376	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CYP2S1—psoriasis	3.85e-06	0.00356	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.79e-06	0.00351	CbGpPWpGaD
Repaglinide—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.72e-06	0.00345	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.71e-06	0.00344	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—IFNG—psoriasis	3.63e-06	0.00336	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.56e-06	0.0033	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—STAT3—psoriasis	3.51e-06	0.00325	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.32e-06	0.00308	CbGpPWpGaD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3.31e-06	0.00307	CbGpPWpGaD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	3.16e-06	0.00293	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—TNF—psoriasis	3.04e-06	0.00281	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYP2S1—psoriasis	3.03e-06	0.00281	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—NFKB1—psoriasis	3.02e-06	0.0028	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—VDR—psoriasis	3e-06	0.00278	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.89e-06	0.00268	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.89e-06	0.00267	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—JUN—psoriasis	2.86e-06	0.00265	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CARM1—psoriasis	2.62e-06	0.00243	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CARM1—psoriasis	2.54e-06	0.00235	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—IL6—psoriasis	2.45e-06	0.00227	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—CARM1—psoriasis	2.42e-06	0.00224	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.4e-06	0.00222	CbGpPWpGaD
Repaglinide—ALB—Platelet degranulation—VEGFA—psoriasis	2.35e-06	0.00218	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—TNF—psoriasis	2.35e-06	0.00218	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.33e-06	0.00216	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—ITGAL—psoriasis	2.26e-06	0.0021	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—LEP—psoriasis	2.26e-06	0.00209	CbGpPWpGaD
Repaglinide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.24e-06	0.00208	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—TP53—psoriasis	2.07e-06	0.00192	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NDUFA5—psoriasis	2.05e-06	0.0019	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NDUFA5—psoriasis	2.04e-06	0.00189	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.02e-06	0.00187	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.91e-06	0.00177	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.9e-06	0.00176	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—IL6—psoriasis	1.9e-06	0.00176	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.89e-06	0.00175	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—TP53—psoriasis	1.89e-06	0.00175	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CARM1—psoriasis	1.88e-06	0.00174	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.87e-06	0.00173	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.8e-06	0.00167	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2S1—psoriasis	1.74e-06	0.00161	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2S1—psoriasis	1.73e-06	0.0016	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—IL6—psoriasis	1.73e-06	0.0016	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—TYK2—psoriasis	1.72e-06	0.0016	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CAT—psoriasis	1.61e-06	0.00149	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.59e-06	0.00147	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CAT—psoriasis	1.56e-06	0.00145	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.51e-06	0.0014	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CARM1—psoriasis	1.48e-06	0.00137	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—VDR—psoriasis	1.44e-06	0.00134	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.38e-06	0.00128	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—NFKB1—psoriasis	1.34e-06	0.00124	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—APOE—psoriasis	1.25e-06	0.00116	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—VEGFA—psoriasis	1.22e-06	0.00113	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—APOE—psoriasis	1.21e-06	0.00113	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—STAT3—psoriasis	1.21e-06	0.00112	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CAT—psoriasis	1.16e-06	0.00107	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NDUFA5—psoriasis	1.1e-06	0.00102	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PPARG—psoriasis	1.09e-06	0.00101	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PPARG—psoriasis	1.06e-06	0.00098	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—TNF—psoriasis	1.04e-06	0.000967	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.04e-06	0.000966	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2S1—psoriasis	9.34e-07	0.000865	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NOS2—psoriasis	9.28e-07	0.00086	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.12e-07	0.000845	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CAT—psoriasis	9.1e-07	0.000843	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.07e-07	0.00084	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—APOE—psoriasis	8.98e-07	0.000832	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CARM1—psoriasis	8.5e-07	0.000787	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CARM1—psoriasis	8.45e-07	0.000783	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—IL6—psoriasis	8.43e-07	0.000781	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.94e-07	0.000736	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.9e-07	0.000732	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—APOE—psoriasis	7.07e-07	0.000655	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARG—psoriasis	6.16e-07	0.00057	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—VEGFA—psoriasis	5.38e-07	0.000498	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CAT—psoriasis	5.23e-07	0.000484	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CAT—psoriasis	5.2e-07	0.000482	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CARM1—psoriasis	4.56e-07	0.000423	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—psoriasis	4.06e-07	0.000376	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—APOE—psoriasis	4.06e-07	0.000376	CbGpPWpGaD
Repaglinide—ALB—Metabolism—APOE—psoriasis	4.04e-07	0.000374	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARG—psoriasis	3.54e-07	0.000328	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARG—psoriasis	3.52e-07	0.000326	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CAT—psoriasis	2.81e-07	0.00026	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—APOE—psoriasis	2.18e-07	0.000202	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARG—psoriasis	1.9e-07	0.000176	CbGpPWpGaD
